Bedrijfsvoering Moderna, Inc.

Aandelen

MRNA

US60770K1079

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nasdaq 22:00:00 23-06-2025 Variatie 5 dagen Verschil t.o.v. 1 jan (%)
25,67 USD -0,89% Intraday-grafiek van Moderna, Inc. -1,27% -38,26%

Uitvoerend comité: Moderna, Inc.

Bedrijfsleider
Beklede functiesVan
Stéphane Bancel

Stéphane Bancel

52 jaar

Chief Executive Officer 01-03-2011
Jerh Collins

Jerh Collins

Chief Tech/Sci/R&D Officer 01-01-2023
James Mock

James Mock

48 jaar

Director of Finance/CFO 06-09-2022
Shannon Klinger

Shannon Klinger

54 jaar

General Counsel 01-06-2021
Corporate Secretary 01-06-2021
Jacqueline Miller

Jacqueline Miller

53 jaar

Chief Tech/Sci/R&D Officer 07-11-2024
Lavina Talukdar

Lavina Talukdar

Investor Relations Contact 01-04-2019
Tracey Franklin

Tracey Franklin

45 jaar

Chief Tech/Sci/R&D Officer 07-11-2024
Human Resources Officer 31-10-2019
Stephen Hoge

Stephen Hoge

49 jaar

President 01-11-2024

Samenstelling van de raad van bestuur: Moderna, Inc.

Directeur
RadenVan
Noubar Afeyan

Noubar Afeyan

61 jaar

Compensation Committee Chair 01-01-2005
Nominating Committee Chair 01-01-2005
Elizabeth Tallett

Elizabeth Tallett

76 jaar

Audit Committee
Compensation Committee
HR Committee
Governance Committee 01-06-2011
Nominating Committee
Compensation Committee Chair 01-01-2011
Audit Committee Chair 01-01-2021
Elizabeth Nabel

Elizabeth Nabel

73 jaar

Compensation Committee Chair
Compensation Committee
HR Committee
Audit Committee 01-04-2021
Governance Committee 01-01-2023
Nominating Committee 01-01-2023
Francois Nader

Francois Nader

68 jaar

Compensation Committee Chair
HR Committee Chair
Governance Committee Chair 11-12-2019
Nominating Committee Chair 11-12-2019
Paul Sagan

Paul Sagan

66 jaar

Audit Committee 01-01-2021
Governance Committee 01-02-2021
Nominating Committee 01-02-2021
Sandra Horning

Sandra Horning

76 jaar

Governance Committee 13-11-2020
Nominating Committee 13-11-2020
Shah Hussain

Shah Hussain

60 jaar

Audit Committee 02-10-2024
David Rubenstein

David Rubenstein

75 jaar

Audit Committee 05-08-2024
Stéphane Bancel

Stéphane Bancel

52 jaar

Director/Board Member 01-03-2011

Voormalige zaakvoerders en bestuurders: Moderna, Inc.

Insider
Beklede functies
VanTot
Kate Cronin
Kate Cronin
Corporate Officer/Principal 12-07-2021 01-04-2025
Melanie Ivarsson
Melanie Ivarsson
Corporate Officer/Principal 30-01-2020 01-11-2024
Stephen Berenson
Stephen Berenson
Director/Board Member 01-10-2017 05-08-2024
Independent Dir/Board Member 01-10-2017 05-08-2024
Robert Langer
Robert Langer
Director/Board Member 01-12-2010 05-08-2024
Founder 01-01-2010 05-08-2024
Independent Dir/Board Member 01-12-2010 05-08-2024
Jonathan Hoggatt
Jonathan Hoggatt
Corporate Officer/Principal 01-10-2023 01-06-2024
Arpa Garay
Arpa Garay
Corporate Officer/Principal 31-05-2022 08-12-2023
Ronald Filippo
Ronald Filippo
Corporate Officer/Principal 01-09-2021 01-11-2023
Juan Andres
Juan Andres
Chief Tech/Sci/R&D Officer 01-08-2017 01-01-2023
Corporate Officer/Principal 01-01-2023 31-05-2023
Brad Miller
Brad Miller
Chief Tech/Sci/R&D Officer 03-01-2023 -
Paul Burton
Paul Burton
Chief Tech/Sci/R&D Officer 06-07-2021 01-01-2023
Stephanie Engels
Stephanie Engels
Corporate Officer/Principal 01-07-2020 01-11-2022
Jorge Gomez
Jorge Gomez
Director of Finance/CFO 09-05-2022 10-05-2022
David Meline
David Meline
Director of Finance/CFO 08-06-2020 09-05-2022
Director of Finance/CFO 10-05-2022 06-09-2022
Corinne Le Goff
Corinne Le Goff
Corporate Officer/Principal 19-01-2021 01-01-2022
Marcello Damiani
Marcello Damiani
Corporate Officer/Principal 01-09-2018 01-01-2022
Tal Zaks
Tal Zaks
Chief Tech/Sci/R&D Officer 01-03-2015 06-07-2021
Lori M. Henderson
Lori M. Henderson
General Counsel 01-04-2018 01-06-2021
Corporate Secretary 01-04-2018 01-06-2021
José M. Vega
José M. Vega
Corporate Officer/Principal 11-01-2021 -
John Lepore
John Lepore
Corporate Officer/Principal 10-08-2020 -
Raymond C. Jordan
Raymond C. Jordan
Corporate Officer/Principal 15-06-2020 -
Lorence Kim
Lorence Kim
Director of Finance/CFO 01-04-2014 08-06-2020
Investor Relations Contact 01-04-2014 08-06-2020
Patrick Norman Bergstedt
Patrick Norman Bergstedt
Corporate Officer/Principal 01-06-2020 -
Moncef Slaoui
Moncef Slaoui
Director/Board Member 01-07-2017 15-05-2020
Independent Dir/Board Member 01-07-2017 15-05-2020
Jennifer Ling Lee
Jennifer Ling Lee
Comptroller/Controller/Auditor - 02-01-2020
Megan E. Pace
Megan E. Pace
Corporate Officer/Principal 01-04-2018 01-01-2020
Peter Hutt
Peter Hutt
Director/Board Member 01-03-2012 09-12-2019
Independent Dir/Board Member 01-03-2012 09-12-2019
Colleen Hussey
Colleen Hussey
Public Communications Contact 01-08-2019 -
Anne Drapeau
Anne Drapeau
Human Resources Officer 01-10-2016 01-05-2019
Robert Dolski
Robert Dolski
Corporate Officer/Principal 01-06-2016 01-05-2019
Stephen Harbin
Stephen Harbin
Corporate Officer/Principal 01-08-2017 01-04-2019
Christoph Brackmann
Christoph Brackmann
Corporate Officer/Principal 01-01-2019 -
Theodore Ashburn
Theodore Ashburn
Corporate Officer/Principal 01-09-2017 01-07-2018
Richard J. Wanstall
Richard J. Wanstall
Director of Finance/CFO 01-07-2014 01-07-2018
Giuseppe Ciaramella
Giuseppe Ciaramella
Chief Tech/Sci/R&D Officer 01-01-2014 01-02-2018
Lee Cooper
Lee Cooper
Corporate Officer/Principal 01-06-2015 31-12-2017
Wendy Arnold
Wendy Arnold
Human Resources Officer 01-01-2014 01-12-2017
Jason Glashow
Jason Glashow
Public Communications Contact 01-12-2017 -
Barry Ticho
Barry Ticho
Corporate Officer/Principal 01-02-2016 01-09-2017
Matthew Stanton
Matthew Stanton
Corporate Officer/Principal 01-04-2014 01-09-2017
Saqib Islam
Saqib Islam
Corporate Officer/Principal 01-02-2016 01-08-2017
Henri A. Termeer
Henri A. Termeer
Director/Board Member - 12-05-2017
Jim Kasinger
Jim Kasinger
General Counsel 01-04-2014 01-05-2017
Corporate Secretary 01-04-2014 01-05-2017
Israel Ruiz
Israel Ruiz
Director/Board Member 01-02-2017 -
Independent Dir/Board Member 01-02-2017 -
Francine Gregoire
Francine Gregoire
Corporate Officer/Principal 01-11-2013 01-03-2016
Theo Melas-Kyriazi
Theo Melas-Kyriazi
Director/Board Member 01-01-2014 01-01-2016
Paula Soteropoulos
Paula Soteropoulos
Corporate Officer/Principal 01-07-2013 01-12-2014
Louis St. Laurence O'Dea
Louis St. Laurence O'Dea
Chief Tech/Sci/R&D Officer 01-01-2012 01-06-2014
John Mendlein
John Mendlein
Director/Board Member 01-02-2019 -
Corporate Officer/Principal 31-01-2018 01-02-2019
Derrick J. Rossi
Derrick J. Rossi
Founder 01-01-2010 -
Kenneth R. Chien
Kenneth R. Chien
Founder 01-01-2010 -
Scott Sudduth
Scott Sudduth
Corporate Officer/Principal - -
John V. W. Reynders
John V. W. Reynders
Chief Tech/Sci/R&D Officer - -
Christine Swenson
Christine Swenson
General Counsel - -
Paula Hammond
Paula Hammond
Consultant / Advisor - -
Axel Bouchon
Axel Bouchon
Corporate Officer/Principal - -
Joe Bolen
Joe Bolen
Chief Tech/Sci/R&D Officer - -
President - -
Kate Beresford O'Malley
Kate Beresford O'Malley
Public Communications Contact - -
Leiden Dworak
Leiden Dworak
Director/Board Member - -
Gregory Licholai
Gregory Licholai
Corporate Officer/Principal - -
Douglas Cole
Douglas Cole
Director/Board Member - -
Founder - -
Igor Smolenov
Igor Smolenov
Chief Tech/Sci/R&D Officer - -

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man14
Vrouw3

Waarvan leden van het uitvoerend comité

Man6
Vrouw2

Waarvan bestuurders

Man8
Vrouw1

Herzieningen

Herziening omzet 1 jaar
-
Herziening omzet 4 maanden
-
Herziening omzet 1 maanden
-
Herziening WPA 1 jaar
-
Herziening WPA 4 maanden
-
ESG MSCI
AA

ESG

Milieu
Sociaal
Bedrijfsvoering
Controverse
ethische controverses
-
controverses inzake mensenrechten
-
controverses belastingsubsidies
-
In overeenstemming met islamitisch financieren
-
Logo Moderna, Inc.
Moderna, Inc. is een biotechnologisch bedrijf gespecialiseerd in het onderzoek naar en de ontwikkeling van therapeutische producten en vaccins voor de behandeling van kanker en infectie-, auto-immuun- en hart- en vaatziektes. De omzet per type inkomsten wordt als volgt onderverdeeld: - inkomsten uit de verkoop van producten (97,4%); - inkomsten uit subsidies (1,4%); - inkomsten uit samenwerkingsovereenkomsten (1,2%). Eind 2023 beschikte het concern over een portfolio van 41 producten in de klinische ontwikkelingsfase, waarvan 6 in fase III, 12 in fase II en 18 in fase I, en van 5 producten in de preklinische ontwikkelingsfase. De geografische verdeling van de omzet is als volgt: Verenigde Staten (27,7%), Europa (19,8%) en overige (52,5%).
Werknemers
5.800
Meer informatie over het bedrijf